(Q36725728)

15 August 2017

1 reference

title

Immunotoxins and central nervous system neoplasia (English)

1 reference

15 August 2017

0 references

Hall WA

1

1 reference

15 August 2017

Fodstad O

2

1 reference

15 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1727147

9 November 2022

publication date

1 January 1992

1 reference

full work available at URL

15 August 2017

https://thejns.org/view/journals/j-neurosurg/76/1/article-p1.xml

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

https://thejns.org/downloadpdf/journals/j-neurosurg/76/1/article-p1.xml

9 November 2022

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

9 November 2022

published in

Journal of Neurosurgery

1 reference

15 August 2017

volume

76

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

1-12

1 reference

Potentiation of cytotoxic activity of immunotoxins on cultured human cells.

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution

9 November 2022

2

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

9 November 2022

5

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Single-chain antigen-binding proteins

9 November 2022

8

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors

9 November 2022

9

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells

9 November 2022

12

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin

9 November 2022

13

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors

9 November 2022

14

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Therapeutic strategies with monoclonal antibodies and immunoconjugates

9 November 2022

16

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors.

9 November 2022

17

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic

9 November 2022

20

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

9 November 2022

22

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Mechanism of the Cytotoxic Action of Alkylating Agents in Mammalian Cells and Evidence for the Removal of Alkylated Groups from Deoxyribonucleic Acid

9 November 2022

23

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Sensitivity of human glioma cells to cytotoxic heteroconjugates.

9 November 2022

24

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Radioimmunotherapy of cancer: clinical studies and limiting factors

9 November 2022

26

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells

9 November 2022

28

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow

9 November 2022

32

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunological and biochemical strategies for the identification of brain tumor-associated antigens

9 November 2022

33

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Receptor-mediated internalization of Pseudomonas toxin by mouse fibroblasts

9 November 2022

34

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Targeted toxin therapy for the treatment of cancer

9 November 2022

35

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells

9 November 2022

36

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Synergistic effect of adriamycin and ricin on L1210 leukemic cells in mice.

9 November 2022

38

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.

9 November 2022

41

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas.

9 November 2022

42

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells

9 November 2022

43

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins.

9 November 2022

44

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice

9 November 2022

45

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

9 November 2022

47

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system

9 November 2022

48

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity

9 November 2022

49

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia

9 November 2022

50

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Comparative permeability of different glioma models to horseradish peroxidase

9 November 2022

51

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Tumor-Associated Carbohydrate Antigens

9 November 2022

52

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Transferrin Receptor on Glioblastoma Multiforme

9 November 2022

54

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Epidermal growth factor receptors on ependymomas and other brain tumors

9 November 2022

55

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts

9 November 2022

56

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours

9 November 2022

57

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunotoxins: a clinical review of their use in the treatment of malignancies

9 November 2022

58

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.

9 November 2022

59

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma

9 November 2022

61

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma

9 November 2022

62

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.

9 November 2022

63

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

9 November 2022

64

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen.

9 November 2022

65

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Evidence for a genetic basis for the class A Thy-1− defect

9 November 2022

66

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report

9 November 2022

68

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

9 November 2022

69

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity

9 November 2022

70

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia

9 November 2022

71

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Continuous cultures of fused cells secreting antibody of predefined specificity

9 November 2022

72

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Variations in response of human brain tumors to BCNU in vitro

9 November 2022

74

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin

9 November 2022

75

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy

9 November 2022

76

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors

9 November 2022

77

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Amplification and overexpression of the EGF receptor gene in primary human glioblastomas

9 November 2022

78

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

9 November 2022

79

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Expression of epidermal growth factor receptors in human brain tumors

9 November 2022

80

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Designer and catalytic antibodies

9 November 2022

81

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Enhancement of chemotherapy agents

9 November 2022

82

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Synthesis of a cytotoxic insulin cross-linked to diphtheria toxin fragment a capable of recognizing insulin receptors

9 November 2022

84

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Interaction of elongation factors EF-G and EF-Tu with a conserved loop in 23S RNA.

9 November 2022

86

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells

9 November 2022

88

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis

9 November 2022

90

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Monoclonal antibodies with cytotoxic reactivities against human gliomas

9 November 2022

91

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults

9 November 2022

92

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening

9 November 2022

93

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier.

9 November 2022

94

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series

9 November 2022

95

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.

9 November 2022

96

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains

9 November 2022

100

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Mechanism of action of the toxic lectins abrin and ricin

9 November 2022

103

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

9 November 2022

Diphtheria Toxin

105

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

9 November 2022

Immunotoxins

107

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.

9 November 2022

108

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Characterization of immunotoxins active against ovarian cancer cell lines

9 November 2022

110

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Evaluation of ricin A-chain immunotoxins directed against human T cells

9 November 2022

111

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Inhibition of Human Acute Lymphoblastic Leukemia Cells by Immunotoxins: Potentiation by Chloroquine

9 November 2022

112

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain

9 November 2022

113

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Cure of experimental human malignant mesothelioma in athymic mice by diphtheria toxin

9 November 2022

114

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy

9 November 2022

115

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro

9 November 2022

116

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Reshaping human antibodies for therapy

9 November 2022

118

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.

9 November 2022

119

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Diphtheria toxin entry into cells is facilitated by low pH.

9 November 2022

121

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Treatment of neuroectodermal brain tumors

9 November 2022

124

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Human hybridomas from malignant gliomas

9 November 2022

125

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon

9 November 2022

126

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Cell kinetics and chemotherapy: a critical review

9 November 2022

130

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells

9 November 2022

131

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Transferrin receptors: Structure and function

9 November 2022

132

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts

9 November 2022

133

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells

9 November 2022

135

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Redesigning nature's poisons to create anti-tumor reagents

9 November 2022

136

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain

9 November 2022

137

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

9 November 2022

138

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

9 November 2022

139

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Effect of a monoclonal anti-carcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen-producing tumor cells

9 November 2022

140

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.

9 November 2022

143

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Epidermal growth factor binding in intracranial neoplasms: preliminary biochemical and clinicopathological findings

9 November 2022

144

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies

9 November 2022

146

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Diphtheria toxin effects on brain-tumor xenografts. Implications for protein-based brain-tumor chemotherapy

9 November 2022

147

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell

9 November 2022

148

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Ricin linked to monophosphopentamannose binds to fibroblast lysosomal hydrolase receptors, resulting in a cell-type-specific toxin

9 November 2022

151

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Studies on the galactose-binding site of ricin and the hybrid toxin Man6P-ricin

9 November 2022

152

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin

9 November 2022

153

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.

9 November 2022

156

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia

9 November 2022

157

1 reference

https://api.crossref.org/works/10.3171/JNS.1992.76.1.0001

9 November 2022

Identifiers

1 reference

15 August 2017

1 reference